Ruckdeschel heads cancer institute at University of Mississippi Medical Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Ruckdeschel was named director of the cancer institute of the University of Mississippi Medical Center as well as Ergon Chair in Cancer Research.

Ruckdeschel, who previously served as the director of the Moffitt Cancer Center, led that institution to NCI Comprehensive Cancer Center designation and to become the third largest clinical cancer program in the U.S.

He then moved to the Barbara Ann Karmanos Cancer Center in Detroit where he re-acquired its NCI comprehensive status and completed the process of making Karmanos a freestanding cancer hospital.

His research was originally in basic immunology but gravitated to clinical and translational research in thoracic malignancies. Ruckdeschel’s career has focused on lung cancer and other thoracic malignancies. He is credited with more than 150 peer reviewed manuscripts and co-editorship of the Textbook of Thoracic Oncology. He is a North American Editor for the Cochrane Lung Cancer Review Group.

Ruckdeschel and Terrance Albrecht co-developed a means to effectively video record patient-physician interactions and applied this technology to understanding clinical trials accrual and end of life decision-making.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login